^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    itraconazole

    Company:
    Generic mfg.
    Drug class:
    CYP51A1 inhibitor
    Related drugs:
    20h
    Itraconazole to Prevent Recurrent Barrett's Esophagus (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, University of Kansas Medical Center | Trial completion date: Jun 2026 --> Dec 2026
    Trial completion date
    |
    itraconazole
    1d
    A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants (clinicaltrials.gov)
    P1, N=30, Recruiting, BeOne Medicines | Not yet recruiting --> Recruiting
    Enrollment open
    |
    itraconazole
    3d
    A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, AbbVie
    New P1 trial
    |
    itraconazole
    3d
    A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants (clinicaltrials.gov)
    P1, N=14, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    itraconazole
    4d
    A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants (clinicaltrials.gov)
    P1, N=51, Completed, Incyte Corporation | Recruiting --> Completed
    Trial completion
    |
    itraconazole
    4d
    A Study to Learn if a Medicine Called Itraconazole Changes How the Body Processes the Study Medicine PF-08642534 in Healthy Adults. (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Pfizer | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    itraconazole
    8d
    Targeting VDAC and Autophagy in Head and Neck Oral Squamous Carcinoma: Synergy of Itraconazole and Hydroxychloroquine. (PubMed, Oral Dis)
    Taken together, these findings support itraconazole as a promising candidate for further in vivo and clinical investigation in selected oral cancers, including HNSCC and OSCC. Nevertheless, the definition of clinical treatment schedules will require additional comprehensive pharmacokinetic, toxicological, and clinical studies.
    Journal
    |
    VDAC1 (Voltage Dependent Anion Channel 1)
    |
    cisplatin • hydroxychloroquine • itraconazole
    9d
    Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions With the Antibody-Drug Conjugate Trastuzumab Deruxtecan. (PubMed, CPT Pharmacometrics Syst Pharmacol)
    The topoisomerase I inhibitor payload (DXd) released from the human epidermal growth factor receptor 2-targeted antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) is eliminated by hepatic uptake via OATP1B1/3, metabolism by CYP3A, biliary excretion via P-glycoprotein and breast cancer resistance protein, and urinary excretion. DDIs with ritonavir and itraconazole simulated by the PBPK model reproduced the clinical DDI study results, indicating that the impact of concomitant medications was not clinically meaningful. These findings suggest that this model may potentially be used for DDI evaluation of future DXd-containing ADCs, aiding in the prediction of DDIs under different scenarios and in specific populations.
    PK/PD data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • itraconazole • ritonavir
    15d
    SHR-A1811-105: Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=17, Completed, Jiangsu HengRui Medicine Co., Ltd. | N=32 --> 17 | Trial completion date: Aug 2026 --> Oct 2025 | Trial primary completion date: Jun 2025 --> Oct 2025 | Recruiting --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    trastuzumab rezetecan (SHR-A1811) • itraconazole • ritonavir
    16d
    Drug Interaction and Food Effect Study of CS0159 (clinicaltrials.gov)
    P1, N=32, Completed, Cascade Pharmaceuticals, Inc | Trial primary completion date: Feb 2027 --> Mar 2026 | Not yet recruiting --> Completed | Trial completion date: Feb 2027 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    itraconazole • rifampicin
    17d
    QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1 trial
    |
    Nubeqa (darolutamide) • itraconazole • MHB088C • rifampicin
    21d
    Clinical characteristics and long-term prognosis of talaromycosis in children with novel and reported inborn errors of immunity. (PubMed, Front Immunol)
    Voriconazole and itraconazole are commonly used for maintenance therapy. Treatment and long-time management remain a challenge. Besides, long lasting anti-fungal and immune boosting therapy may be necessary, while HSCT intervention could provide potential benefits.
    Observational data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PLCG2 (Phospholipase C Gamma 2) • IL7R (Interleukin 7 Receptor) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CD40LG (CD40 ligand) • DOCK8 (Dedicator Of Cytokinesis 8) • CARD9 (Caspase Recruitment Domain Family Member 9) • IL2RG (Interleukin 2 Receptor Subunit Gamma)
    |
    itraconazole